Sort by
Refine Your Search
-
cultured human and rodent cardiomyocytes, engineered heart tissues, and animal models of heart development and disease. Specifically, you will engage in basic science and applied research to explore
-
, and to interact regularly with Dr. Jonathan Campbell to design and execute experimental studies involving animal and cell-based models of metabolic disease. In addition, will also perform the following
-
independent research activities under the guidance of a faculty mentor in preparation for a full time academic or research career. Conduct research on computational modeling of cortical neuron activation by
-
by two NIDA-funded grants. The first project, NEURONIC, utilizes a nasal spray paradigm to assess reactions to nicotine in a controlled, laboratory setting as a model of risk for addiction
-
of studies of HLA-E-VL9 antibodies in cancer models (in vitro or animals) Other studies on which you and Drs. Haynes and Azoitei agree In addition, you will need to: Present scientific results at meetings and
-
keratinocyte differentiation and cancer biology utilizing cultured cells and animal models of skin diseases. Responsibilities include: Development of new and implementation and modification of existing
-
processes that are disrupted across a range of conditions, such as major depression and autism spectrum disorders. Qualifications: The candidate must have a Ph.D. in neuroscience or a related discipline using
-
models using a wide variety of data, including clinical, wearable devices, neuroimaging, and –omics data from electronic health record, registry, and research initiatives; and (2) develop and apply novel
-
restoration of function. The successful applicant will combine computational modeling, engineering optimization, and in vivo experiments to advance understanding and application of electrical block of neural
-
cells with organoid culture, which will create novel pre-clinical disease models. 3.Identifying vulnerabilities in treatment-resistant epithelial cancers. 4.Developing novel therapies targeting oncogenic